Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 11:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 80 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Regular Injection Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Healthy Normal Volunteers Looking at Exposure and Effects of Multiple Doses of Technosphere® Insulin (TI) Using the Gen2C Inhaler

NCT01490762
View directory record Official record
Conditions
Healthy
Interventions
Technosphere Insulin Inhalation Powder using the Gen2C inhaler, Regular Human Insulin
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Sep 5, 2026, 11:55 PM EDT
Completed Early Phase 1 Interventional

Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy

NCT01894451
View directory record Official record
Conditions
Inflammatory Breast Carcinoma
Interventions
89Zr-bevacizumab, FDG-PET/CT, MRI scan, Tumor biopsies
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 5, 2026, 11:55 PM EDT
Completed Phase 2 Interventional Results available

Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus

NCT00774800
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20), Liquid meal
Drug · Other
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 5, 2026, 11:55 PM EDT
Active, not recruiting Phase 2 Interventional

Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy

NCT05069038
View directory record Official record
Conditions
Breast Cancer
Interventions
Palbociclib 125mg
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 5, 2026, 11:55 PM EDT
Completed Not applicable Interventional Results available

Selecting Insulin Analogs for Closed-Loop Control Using Multiplex Pharmacokinetic Profiling

NCT01684943
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Multiplex pharmacokinetic profiling, Continuous insulin monitoring
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 5, 2026, 11:55 PM EDT
Completed Phase 2 Interventional

Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT05158023
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo Comparator, ASLAN004
Drug · Biological
Lead sponsor
ASLAN Pharmaceuticals
Other
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
47
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Encino, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Sep 5, 2026, 11:55 PM EDT
Active, not recruiting Phase 2 Interventional

Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes

NCT04542148
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Preterm Birth, Pregnancy, High Risk, Diabetes, Gestational
Interventions
Sliding Scale Insulin, Up-Titration of Home Insulin, Continuous Insulin Infusion, Dexcom G6 Professional Continuous Glucose Monitor
Drug · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Up to 50 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Birmingham, Alabama • Portland, Oregon • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 5, 2026, 11:55 PM EDT
Not listed Not applicable Interventional

Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency

NCT01804413
View directory record Official record
Conditions
Adults Growth Hormone Deficiency.
Interventions
Pegvisomant, Regular insulin
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Sep 5, 2026, 11:55 PM EDT
Recruiting Phase 3 Interventional

A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

NCT07422480
View directory record Official record
Conditions
Myelodysplastic Syndrome, Anemia
Interventions
Elritercept, Epoetin Alfa
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
25
States / cities
Gilbert, Arizona • Duarte, California • Santa Rosa, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 5, 2026, 11:55 PM EDT
Completed Phase 3 Interventional Results available

An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus

NCT02561078
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Human regular U-500 insulin (CSII), Human regular U-500 insulin (MDI)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
52
States / cities
Mobile, Alabama • Concord, California • Fresno, California + 48 more
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Sep 5, 2026, 11:55 PM EDT
Completed Phase 4 Interventional Results available

Veterans Inpatient Insulin Study and Transition to Outpatient Therapy

NCT00821795
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
NPH/Regular 70/30 mix, insulin aspart protamine/insulin aspart 70/30 mix
Drug
Lead sponsor
Dennis G. Karounos, M.D.
Federal
Eligibility
40 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 5, 2026, 11:55 PM EDT
Completed Not applicable Interventional Results available

Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study B

NCT00858273
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Antioxidant supplement, Diabetes treatment, Regular Insulin
Dietary Supplement · Other · Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 21 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Sep 5, 2026, 11:55 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening

NCT04904757
View directory record Official record
Conditions
Mammographic Breast Density, Mammography
Interventions
Contrast-enhanced spectral mammography (CESM)
Device
Lead sponsor
University of Virginia
Other
Eligibility
40 Years to 69 Years · Female only
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 16, 2022 · Synced Sep 5, 2026, 11:55 PM EDT
Completed Phase 2 Interventional

A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro

NCT01000922
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Regular Human Insulin, Lispro, VIAject, VIAject 50%, VIAject/Insulin Glargine, Insulin Glargine/VIAject
Drug
Lead sponsor
Biodel
Industry
Eligibility
19 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Jul 28, 2015 · Synced Sep 5, 2026, 11:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Actrapid, in Healthy Subjects.

NCT00719108
View directory record Official record
Conditions
Diabetes
Interventions
Wosulin R, Actrapid
Biological
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 45 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 26, 2012 · Synced Sep 5, 2026, 11:55 PM EDT
Completed No phase listed Observational

Impact of Exenatide on Sleep Duration

NCT01416649
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Exenatide
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 5, 2026, 11:55 PM EDT
Completed Phase 3 Interventional Results available

A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors

NCT03417245
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
fitusiran, factor concentrates
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
12 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
8
States / cities
Little Rock, Arkansas • Gainesville, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2022 · Synced Sep 5, 2026, 11:55 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

NCT03974113
View directory record Official record
Conditions
Hemophilia
Interventions
Fitusiran
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
1 Year to 11 Years · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Los Angeles, California • Hackensack, New Jersey • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 5, 2026, 11:55 PM EDT
Terminated Not applicable Interventional

Comparison of Tendon Transfer, Botox Injections and Ongoing Treatment in Hemiplegic Cerebral Palsy

NCT00250081
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Upper Extremity Tendon transfer, Botulinum Toxin injections in Upper Extremity, Regularly ongoing therapy
Procedure
Lead sponsor
Shriners Hospitals for Children
Other
Eligibility
4 Years to 17 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
10
States / cities
Sacramento, California • Wilmington, Delaware • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Sep 5, 2026, 11:55 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1

NCT06694805
View directory record Official record
Conditions
HIV Infections
Interventions
CAB LA + RPV LA, Oral ART
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
12 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
39
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 5, 2026, 11:55 PM EDT
Terminated Phase 4 Interventional Results available

Antiseizure Medication in Seizure Networks at Early Acute Brain Injury

NCT06081283
View directory record Official record
Conditions
Brain Injuries, Acute, Brain Injuries, Traumatic, Brain Ischemia, Brain Hypoxia, Hypoxia-Ischemia, Brain, Heart Arrest, Stroke, Intracranial Hemorrhages, Coma, Persistent Vegetative State
Interventions
Phenobarbital Sodium Injection, Levetiracetam, Lacosamide Injectable Product, Valproate Sodium, Fosphenytoin
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Months to 70 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced Sep 5, 2026, 11:55 PM EDT
Terminated Phase 4 Interventional

Shoulder Adhesive Capsulitis and Ambulatory Continuous Interscalene Nerve Blocks

NCT00875862
View directory record Official record
Conditions
Adhesive Capsulitis, Post-operative Pain
Interventions
Interscalene catheter with Ropivicaine or normal saline
Procedure
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Sep 5, 2026, 11:55 PM EDT
Completed Phase 3 Interventional Results available

A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia

NCT03345979
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole Lauroxil, Paliperidone Palmitate
Combination Product · Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
16
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Cerritos, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 5, 2026, 11:55 PM EDT
Completed Phase 4 Interventional Results available

Imaging of Osteonecrosis With Ferumoxytol-Enhanced MRI

NCT02893293
View directory record Official record
Conditions
Osteonecrosis
Interventions
Ferumoxytol-enhanced magnetic resonance imaging, Magentic Resonance Imaging
Drug · Device
Lead sponsor
Stanford University
Other
Eligibility
8 Years to 40 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Sep 5, 2026, 11:55 PM EDT